Merck & Co. Gets $2.13B Boost From KRAS Deal
Merck & Co.'s stock has received a significant boost following a deal worth USD 2.13 billion to secure global rights for an investigational KRAS G12D cancer drug.
The deal, announced on September 28, 2026, with SciBrunch Therapeutics, includes a USD 400 million upfront payment plus milestone payments.
Merck & Co.'s stock price increased by 0.54 percent to EUR 131.05 at Lang & Schwarz on September 29, 2026, following the news.
The company has secured preclinical oral KRAS G12D inhibitor SPR2015 through this agreement.